BR9908030A - Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado - Google Patents

Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado

Info

Publication number: BR9908030A
Authority: BR; Brazil
Prior art keywords: treatment; cyclooxygenase; disorder; processes; individual
Prior art date: 1998-11-30

Application number

BR9908030-3A

Other languages

English (en)

Portuguese (pt)

Inventor

Danchen Gao

Anthony J Hlinak

Ahmad M Mazhary

Margaret B Woodhull Vaughn

Original Assignee

Searle & Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-11-30

Filing date

1999-11-30

Publication date

2000-11-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22332446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9908030(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-11-30 Application filed by Searle & Co filed Critical Searle & Co

2000-11-28 Publication of BR9908030A publication Critical patent/BR9908030A/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Biophysics (AREA)
Ophthalmology & Optometry (AREA)
Pulmonology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Virology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)

BR9908030-3A 1998-11-30 1999-11-30 Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado BR9908030A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11033398P	1998-11-30	1998-11-30
PCT/US1999/028411 WO2000032189A1 (fr)	1998-11-30	1999-11-30	Compositions a base de celecoxib

Publications (1)

Publication Number	Publication Date
BR9908030A true BR9908030A (pt)	2000-11-28

Family

ID=22332446

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9908030-3A BR9908030A (pt)	1998-11-30	1999-11-30	Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado

Country Status (47)

Country	Link
US (4)	US20050267189A1 (fr)
EP (1)	EP1049467B1 (fr)
JP (1)	JP3563036B2 (fr)
KR (2)	KR100501034B1 (fr)
CN (2)	CN1154490C (fr)
AP (1)	AP1637A (fr)
AR (1)	AR020015A1 (fr)
AT (1)	ATE225650T1 (fr)
AU (1)	AU748851B2 (fr)
BG (1)	BG64938B1 (fr)
BR (1)	BR9908030A (fr)
CA (1)	CA2319201C (fr)
CR (2)	CR6210A (fr)
CU (1)	CU20000176A7 (fr)
DE (1)	DE69903404T2 (fr)
DK (1)	DK1049467T3 (fr)
EA (1)	EA003363B1 (fr)
EE (1)	EE04834B1 (fr)
ES (1)	ES2185412T3 (fr)
GC (1)	GC0000114A (fr)
GE (1)	GEP20022784B (fr)
GT (1)	GT199900203A (fr)
HN (1)	HN1999000210A (fr)
HR (1)	HRP20000434B1 (fr)
HU (1)	HUP0100867A3 (fr)
IL (1)	IL136532A (fr)
IS (1)	IS5555A (fr)
MA (1)	MA26709A1 (fr)
ME (1)	ME00416B (fr)
NO (1)	NO329912B1 (fr)
NZ (1)	NZ505762A (fr)
OA (1)	OA11616A (fr)
PA (1)	PA8486001A1 (fr)
PE (1)	PE20001349A1 (fr)
PL (1)	PL200957B1 (fr)
PT (1)	PT1049467E (fr)
RS (1)	RS50158B (fr)
SA (1)	SA99191255B1 (fr)
SI (1)	SI1049467T1 (fr)
SK (1)	SK283510B6 (fr)
TN (1)	TNSN99223A1 (fr)
TR (1)	TR200002207T1 (fr)
TW (1)	TW579295B (fr)
UA (1)	UA58576C2 (fr)
UY (2)	UY25826A1 (fr)
WO (1)	WO2000032189A1 (fr)
ZA (1)	ZA200002722B (fr)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9720061D0 (en)	1997-09-19	1997-11-19	Crosfield Joseph & Sons	Metal compounds as phosphate binders
SA99191255B1 (ar)	1998-11-30	2006-11-25	جي دي سيرل اند كو	مركبات سيليكوكسيب celecoxib
ATE425749T1 (de) *	1999-01-27	2009-04-15	Cornell Res Foundation Inc	Behandlung von mit her-2/neu-uberexprimierung einhergehendem krebs
DE60016191T2 (de) *	1999-12-08	2005-12-22	Pharmacia Corp., Chicago	Cyclooxygenase-2 hemmer enthaltende zusammensetzungen mit schnellem wirkungseintritt
JP2004500358A (ja) *	1999-12-08	2004-01-08	ファルマシア　コーポレイション	バイオアベイラビリティーが増加した固体状態のセレコキシブ
BR0008059A (pt) *	1999-12-08	2002-03-26	Pharmacia Corp	Composições de valdecoxib
US20020015735A1 (en) *	1999-12-22	2002-02-07	Hedden David B.	Sustained-release formulation of a cyclooxygenase-2 inhibitor
IL150353A0 (en) *	1999-12-22	2002-12-01	Pharmacia Corp	Dual-release compositions of a cyclooxygenase-2 inhibitor
AR035642A1 (es) *	2000-05-26	2004-06-23	Pharmacia Corp	Uso de una composicion de celecoxib para el alivio rapido del dolor
AU2001275004A1 (en) *	2000-06-01	2001-12-11	Pharmacia Corporation	Use of cox2 inhibitors for treating skin injury from exposure to ultraviolet radiation
EP1353664A2 (fr) *	2000-06-08	2003-10-22	The Board Of Regents, The University Of Texas System	Derives heterocycliques et techniques d'utilisation pour le traitement d'infection par le charbon
US6589557B2 (en) *	2000-06-15	2003-07-08	Acusphere, Inc.	Porous celecoxib matrices and methods of manufacture thereof
CN1638739A (zh) *	2000-08-18	2005-07-13	法玛西雅厄普约翰美国公司	治疗成瘾性障碍的化合物
PT1309315E (pt) *	2000-08-18	2006-09-29	Pharmacia Corp	Formulacao oral de desintegracao rapida de valdecoxib
IN191090B (fr) *	2000-08-29	2003-09-20	Ranbanx Lab Ltd
PE20020351A1 (es) *	2000-09-11	2002-06-14	Novartis Ag	Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2
US6982251B2 (en)	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
US7115565B2 (en) *	2001-01-18	2006-10-03	Pharmacia & Upjohn Company	Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
ES2274013T3 (es)	2001-01-26	2007-05-16	Schering Corporation	Combinaciones de activador(es) del receptor activado por el proliferador de los peroxisomas (ppar) e inhibidor(es)m de la absorcion de estelores y tratamientos para trastornos vasculares.
CA2434430A1 (fr)	2001-01-26	2002-08-01	Harry R. Davis	Utilisation de composes d'azetidinone substituee pour le traitement de la sitosterolemie
US7071181B2 (en)	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US20030105141A1 (en) *	2001-04-17	2003-06-05	Ping Gao	Finely self-emulsifiable pharmaceutical composition
DE10129320A1 (de)	2001-06-19	2003-04-10	Norbert Mueller	Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
UA80682C2 (en) *	2001-08-06	2007-10-25	Pharmacia Corp	Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
US20030114527A1 (en) *	2001-08-31	2003-06-19	Karnachi Anees Abdulquadar	Pharmaceutical composition
AU2002336609B2 (en)	2001-09-21	2006-08-24	Merck Sharp & Dohme Corp.	Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en)	2001-09-21	2006-06-06	Schering Corporation	Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
BR0213973A (pt) *	2001-11-07	2004-08-31	Pharmacia Corp	Composições de valdecoxib que se desintegram intra-oralmente preparadas pelo processo de granulação em leito fluidizado
US7790905B2 (en)	2002-02-15	2010-09-07	Mcneil-Ppc, Inc.	Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en)	2002-02-15	2011-04-19	University Of South Florida	Pharmaceutical co-crystal compositions
JP4906233B2 (ja)	2002-03-01	2012-03-28	ユニバーシティーオブサウスフロリダ	少なくとも１種の有効薬剤成分を含有する多構成要素固相
CA2479665C (fr) *	2002-03-20	2011-08-30	Elan Pharma International Ltd.	Compositions nanoparticulaires d'inhibiteurs d'angiogenese
GB0209257D0 (en) *	2002-04-23	2002-06-05	Novartis Ag	Organic compounds
US6864373B2 (en)	2002-05-13	2005-03-08	Pharmacia Corporation	Stable amorphous celecoxib composite and process therefor
AR040588A1 (es)	2002-07-26	2005-04-13	Schering Corp	Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
AU2003249510A1 (en) *	2002-08-12	2004-02-25	Ranbaxy Laboratories Limited	A parenteral dosage form of selective cox-2 inhibitors
JP2006514687A (ja) *	2002-08-30	2006-05-11	ファルマシアコーポレイション	再現性のある医薬放出特性を示す医薬固形投与形態
WO2004043457A1 (fr)	2002-11-06	2004-05-27	Schering Corporation	Inhibiteurs d'absorption de cholesterol pour le traitement de troubles auto-immuns
DE50309605D1 (de)	2002-11-22	2008-05-21	Gruenenthal Gmbh	Verwendung von (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexan-1,3-diol zur Behandlung von Entzündungsschmerz
US8183290B2 (en)	2002-12-30	2012-05-22	Mcneil-Ppc, Inc.	Pharmaceutically acceptable propylene glycol solvate of naproxen
CN1756756A (zh)	2003-03-07	2006-04-05	先灵公司	取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7235543B2 (en)	2003-03-07	2007-06-26	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US20060172019A1 (en) *	2003-03-07	2006-08-03	Ralston Stuart H	Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders
WO2004081004A1 (fr)	2003-03-07	2004-09-23	Schering Corporation	Composes d'azetidinone substitues, formulations et utilisations de ceux-ci pour traiter l'hypercholesterolemie
US7459442B2 (en)	2003-03-07	2008-12-02	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US20040220187A1 (en) *	2003-04-22	2004-11-04	Pharmacia Corporation	Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders
US6916852B2 (en) *	2003-05-12	2005-07-12	University Of Tennessee Research Foundation	Method for regulation of microvascular tone
UY28501A1 (es)	2003-09-10	2005-04-29	Astrazeneca Uk Ltd	Compuestos químicos
DE10355461A1 (de)	2003-11-27	2005-06-23	Bayer Healthcare Ag	Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
SI1742922T1 (sl)	2004-04-01	2016-07-29	Zoetis Serivices Llc	Kristalinični pirazolni derivat
MX2007002781A (es) *	2004-09-09	2009-02-12	Bayer Animal Health Gmbh	Composición farmacéutica.
EP1833476A1 (fr)	2004-11-23	2007-09-19	PLIVA HRVATSKA d.o.o.	Composition pharmaceutique de celecoxib a liberation prolongee
MY157620A (en)	2006-01-31	2016-06-30	Cytochroma Dev Inc	A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
RU2309732C1 (ru) *	2006-03-13	2007-11-10	Олег Ильич Эпштейн	Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
TWI394753B (zh)	2006-03-17	2013-05-01	Otsuka Pharma Co Ltd	新穎替妥牟拉（ｔｅｔｏｍｉｌａｓｔ）晶體
EP2132173B1 (fr) *	2007-02-26	2015-10-07	Merck Sharp & Dohme Corp.	Formulations pour inhibiteurs de la cathepsine k
PE20081891A1 (es) *	2007-03-22	2008-12-27	Opko Health Inc	Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
GB0714670D0 (en)	2007-07-27	2007-09-05	Ineos Healthcare Ltd	Use
GB0720220D0 (en)	2007-10-16	2007-11-28	Ineos Healthcare Ltd	Compound
US8372431B2 (en)	2007-10-26	2013-02-12	Bial-Portela & C.A., S.A.	Pharmaceutical composition comprising licarbazepine acetate
WO2009063367A1 (fr) *	2007-11-15	2009-05-22	Pfizer Products Inc.	Formes galéniques comprenant du célécoxib permettant un soulagement de la douleur à la fois rapide et prolongé
US8372432B2 (en)	2008-03-11	2013-02-12	Depomed, Inc.	Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
CN102105136B (zh)	2008-03-11	2014-11-26	蒂宝制药公司	包含非-阿片类止痛剂和阿片类止痛剂的组合的胃滞留型缓释剂型
WO2010095065A1 (fr) *	2009-02-17	2010-08-26	Koninklijke Philips Electronics N.V.	Imagerie fonctionnelle
PL387415A1 (pl) *	2009-03-06	2010-09-13	Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna	Kompozycja farmaceutyczna zawierająca celekoksyb oraz sposób jej wytwarzania
EA201171282A1 (ru) *	2009-04-24	2012-05-30	Айсьютика Пти Лтд.	Способ производства коммерческих порошков, содержащих нано- и микрочастицы
EA201171280A1 (ru) *	2009-04-24	2012-09-28	Айсьютика Пти Лтд.	Способ улучшения характеристик растворения биологически активного материала
CA2759102A1 (fr) *	2009-04-24	2010-10-28	Iceutica Pty Ltd	Une composition herbicide ayant une fraction a grand volume de mancozeb
CN102740835A (zh) *	2009-04-24	2012-10-17	伊休蒂卡有限公司	包封的纳米颗粒在工业规模的制备
BRPI1013835B8 (pt) *	2009-04-24	2021-05-25	Iceutica Pty Ltd	método para produção de material biologicamente ativo de nanopartícula e/ou micropartícula, composição compreendendo referido material, composição farmacêutica, uso da mesma, e, método para produção de uma composição farmacêutica, de um produto veterinário e de um produto agrícola
EP2432459A2 (fr) *	2009-05-20	2012-03-28	Ranbaxy Laboratories Limited	Compositions orales de celecoxib
GB0913525D0 (en)	2009-08-03	2009-09-16	Ineos Healthcare Ltd	Method
WO2011050944A1 (fr)	2009-10-28	2011-05-05	Ratiopharm Gmbh	Formulations contenant du célécoxib
US20110150989A1 (en) *	2009-12-22	2011-06-23	Mallinkckrodt Inc.	Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
US9198861B2 (en)	2009-12-22	2015-12-01	Mallinckrodt Llc	Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
EP2340819A1 (fr) *	2009-12-23	2011-07-06	Laboratorios Del. Dr. Esteve, S.A.	Compositions comprenant du venlafaxine et du célécoxib pour le traitement de la douleur
EP2340818A1 (fr) *	2009-12-23	2011-07-06	Laboratorios Del. Dr. Esteve, S.A.	Co-cristaux de venlafaxine et célécoxib
GB201001779D0 (en)	2010-02-04	2010-03-24	Ineos Healthcare Ltd	Composition
CN102000018B (zh) *	2010-02-09	2012-07-04	浙江大学宁波理工学院	一种含塞来昔布的固体分散物及其制备方法和应用
US8858963B1 (en)	2011-05-17	2014-10-14	Mallinckrodt Llc	Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9050335B1 (en)	2011-05-17	2015-06-09	Mallinckrodt Llc	Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8741885B1 (en)	2011-05-17	2014-06-03	Mallinckrodt Llc	Gastric retentive extended release pharmaceutical compositions
US20140093563A1 (en) *	2011-06-13	2014-04-03	Ranbaxy Laboratories Limited	Febuxostat compositions
CN102949403A (zh) *	2011-08-24	2013-03-06	天津药物研究院	一种塞来昔布组合物及制备方法和用途
CN102949402A (zh) *	2011-08-24	2013-03-06	天津药物研究院	一种塞来昔布组合物及制备方法和用途
CN102920676B (zh) *	2012-12-04	2014-08-20	山东省立医院	一种塞来昔布咀嚼片及其制备方法
CN103989657B (zh) *	2013-02-20	2016-10-05	四川国为制药有限公司	一种含有塞来昔布的胶囊剂
CA2905649A1 (fr) *	2013-03-15	2014-09-18	The Penn State Research Foundation	Compositions et procedes comprenant du celecoxib et de la plombagine associes au traitement du cancer
CN103230382B (zh) *	2013-04-17	2015-12-09	贵州联盛药业有限公司	塞来昔布泡腾片及其制备方法
CN103585164B (zh) *	2013-11-08	2015-12-02	海南合瑞制药股份有限公司	一种溶出度增加的塞来昔布固体组合物及其制备方法和应用
CN104027319A (zh) *	2014-06-25	2014-09-10	万特制药(海南)有限公司	一种塞来昔布分散片及其制备方法
KR101652332B1 (ko)	2014-10-31	2016-09-01	(주) 킴스제약	관절염 치료용 혼합조성물 및 관절염 치료용 혼합제제의 제조방법
CN104721146A (zh) *	2015-04-03	2015-06-24	海南海力制药有限公司	塞来昔布溶剂分散体、微丸胶囊及其制备方法
WO2016191744A1 (fr)	2015-05-28	2016-12-01	Dr. Reddy's Laboratories Ltd.	Composition orale de célécoxib pour le traitement de la douleur
KR101710792B1 (ko)	2015-07-14	2017-02-28	주식회사 유영제약	세레콕시브 및 트라마돌을 함유하는 약제학적 조성물
CN104983714A (zh) *	2015-08-06	2015-10-21	苏州二叶制药有限公司	一种塞来昔布胶囊及其制备方法
CN105125520A (zh) *	2015-09-29	2015-12-09	深圳瑞多力泰医药科技实业有限公司	一种塞来昔布制剂及其制备方法和控制方法
HUP1500618A2 (en)	2015-12-16	2017-06-28	Druggability Tech Ip Holdco Ltd	Complexes of celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical composition containing them
CN105343030A (zh) *	2015-12-16	2016-02-24	钟柏根	一种塞来昔布胶囊及其制备方法
KR101625344B1 (ko)	2015-12-21	2016-06-08	주식회사 유영제약	세레콕시브 및 둘록세틴을 함유하는 약제학적 조성물
US20170348419A1 (en) *	2016-06-06	2017-12-07	NuBioPharma, LLC	Oral liquid suspensions
KR102002906B1 (ko) *	2016-10-18	2019-07-23	경동제약 주식회사	셀레콕시브를 포함하는 정제
US10350171B2 (en)	2017-07-06	2019-07-16	Dexcel Ltd.	Celecoxib and amlodipine formulation and method of making the same
AU2019412533B2 (en) *	2018-12-28	2025-09-04	Gnt Pharma Co., Ltd.	Compositions and methods for treating neurodegenerative disorders
WO2020214791A1 (fr) *	2019-04-18	2020-10-22	Nangenex Nanotechnology Incorporated	Compositions de célécoxib et leurs méthodes d'utilisation
CN110604722B (zh) *	2019-09-19	2020-12-11	山东创新药物研发有限公司	一种塞来昔布的固体分散方法及塞来昔布胶囊的制备方法
WO2021124044A1 (fr)	2019-12-16	2021-06-24	Themis Medicare Limited	Composition pharmaceutique d'inhibiteurs de cyclo-oxygénase - 2
IL294033A (en) *	2020-01-16	2022-08-01	Eisai R&D Man Co Ltd	Drug substance of lemborexant and medicinal composition comprising same
CN112263562B (zh) *	2020-09-25	2022-09-30	石药集团欧意药业有限公司	一种塞来昔布胶囊组合物的制备方法
CN116761589A (zh) *	2020-12-18	2023-09-15	株式会社大熊制药	含1-(5-(2,4-二氟苯基)-1-((3-氟苯基)磺酰基)-4-甲氧基-1h-吡咯-3-基)-n-甲基甲胺的口服给药新制剂
CN114681470A (zh)	2020-12-28	2022-07-01	雷迪博士实验室有限公司	治疗疼痛的方法
CN112933085B (zh) *	2020-12-28	2021-12-21	中以海德人工智能药物研发股份有限公司	一种化合物在制备治疗或预防病毒性肝炎用药物中的应用
CN113144212B (zh) *	2021-03-15	2022-02-11	上海英诺富成生物科技有限公司	一种塞来昔布的前体药物及其制备方法与应用
CN113402463B (zh) *	2021-07-08	2023-12-26	江南大学	一种塞来昔布微晶、负载塞来昔布微晶的温敏性凝胶及其制备方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5644A (en) *		1848-06-20		Improvement in apparatus for the increase of the speed of vessels
EP0001247A1 (fr)	1977-09-14	1979-04-04	Kanebo, Ltd.	Composition pharmaceutique contenant de la nifédipine et procédé pour sa préparation.
US5264446A (en) *	1980-09-09	1993-11-23	Bayer Aktiengesellschaft	Solid medicament formulations containing nifedipine, and processes for their preparation
DE3270785D1 (en) *	1981-10-29	1986-05-28	Bayer Ag	Process for preparing solid fast-releasing drug formulations of dihydropyridines
IT1206166B (it) *	1984-07-26	1989-04-14	Sigma Tau Ind Farmaceuti	Dispositivo per rilasciare una sostanza in un fluido di dissoluzione con cinetica di ordine zero e procedimento per la sua preparazione
US4826689A (en) *	1984-05-21	1989-05-02	University Of Rochester	Method for making uniformly sized particles from water-insoluble organic compounds
US5266581A (en)	1984-07-04	1993-11-30	Bayer Aktiengesellschaft	Solid composition containing dihydropyridine, PVP and PVPP
IE58110B1 (en) *	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
US4666705A (en) *	1985-06-03	1987-05-19	E. R. Squibb & Sons, Inc.	Controlled release formulation
US5112619A (en)	1985-11-12	1992-05-12	Eli Lilly And Company	Orally administerable sustained release pharmaceutical formulation
US4971790A (en)	1986-02-07	1990-11-20	Alza Corporation	Dosage form for lessening irritation of mocusa
DE3610037A1 (de) *	1986-03-21	1987-09-24	Schering Ag	Nifedipinkombinationspraeparat
FR2602423B1 (fr)	1986-08-08	1989-05-05	Ethypharm Sa	Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
IT1201136B (it) *	1987-01-13	1989-01-27	Resa Farma	Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
GB8702411D0 (en)	1987-02-03	1987-03-11	Zyma Sa	Swellable pellets
US4786503A (en) *	1987-04-06	1988-11-22	Alza Corporation	Dosage form comprising parallel lamine
IT1215726B (it)	1988-01-18	1990-02-22	Alfa Wassermann Spa	Formulazioni galeniche a cessione programmata.
FR2627696B1 (fr)	1988-02-26	1991-09-13	Fournier Innovation Synergie	Nouvelle forme galenique du fenofibrate
US4866848A (en) *	1988-10-24	1989-09-19	Alexander Agelidis	Instrument for subdividing angles into halves, thirds or fifths
US5342624A (en) *	1989-02-16	1994-08-30	British Technology Group Ltd.	Dispensing device
HU203041B (en) *	1989-03-14	1991-05-28	Egyt Gyogyszervegyeszeti Gyar	Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
US5776493A (en) *	1989-07-14	1998-07-07	Alza Corporation	Oral osmotic device for delivery of nystatin with hydrogel driving member
US5474784A (en) *	1990-03-02	1995-12-12	British Technology Group Limited	Dispensing device
FR2669915B1 (fr)	1990-11-29	1993-01-29	Atochem	Particules de chlorure de magnesium a structure polyedre, composante catalytique supportee sur ces particules, procedes de fabrication de ces produits et des polyolefines obtenues a partir de cette composante catalytique.
US5552160A (en) *	1991-01-25	1996-09-03	Nanosystems L.L.C.	Surface modified NSAID nanoparticles
US6048850A (en)	1992-09-22	2000-04-11	Young; Donald A.	Method of inhibiting prostaglandin synthesis in a human host
US5474995A (en) *	1993-06-24	1995-12-12	Merck Frosst Canada, Inc.	Phenyl heterocycles as cox-2 inhibitors
US5622719A (en) *	1993-09-10	1997-04-22	Fuisz Technologies Ltd.	Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5540669A (en) *	1993-09-30	1996-07-30	Becton, Dickinson And Company	Iontophoretic drug delivery system and method for using same
KR100263817B1 (ko)	1993-11-30	2000-08-16	윌리암스 로저 에이	염증치료용 치환 피라졸일벤젠술폰아미드
US5466823A (en)	1993-11-30	1995-11-14	G.D. Searle & Co.	Substituted pyrazolyl benzenesulfonamides
WO1995018799A1 (fr)	1994-01-10	1995-07-13	Merck Frosst Canada Inc.	Heterocycles phenyliques utilises comme inhibiteurs de cox-2
US5543099A (en) *	1994-09-29	1996-08-06	Hallmark Pharmaceutical, Inc.	Process to manufacture micronized nifedipine granules for sustained release medicaments
US5965161A (en)	1994-11-04	1999-10-12	Euro-Celtique, S.A.	Extruded multi-particulates
US5739166A (en) *	1994-11-29	1998-04-14	G.D. Searle & Co.	Substituted terphenyl compounds for the treatment of inflammation
US5585115A (en)	1995-01-09	1996-12-17	Edward H. Mendell Co., Inc.	Pharmaceutical excipient having improved compressability
US5518738A (en)	1995-02-09	1996-05-21	Nanosystem L.L.C.	Nanoparticulate nsaid compositions
US5591456A (en) *	1995-02-10	1997-01-07	Nanosystems L.L.C.	Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5633272A (en) *	1995-02-13	1997-05-27	Talley; John J.	Substituted isoxazoles for the treatment of inflammation
TW493991B (en)	1995-05-08	2002-07-11	Novartis Ag	Pharmaceutical composition for oral administration of active agent having low water solubility and process for preparation of the same
AU708964B2 (en)	1995-05-25	1999-08-19	G.D. Searle & Co.	Method of preparing 3-haloalkyl-1h-pyrazoles
US5643933A (en)	1995-06-02	1997-07-01	G. D. Searle & Co.	Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
GB9511220D0 (en)	1995-06-02	1995-07-26	Glaxo Group Ltd	Solid dispersions
US5756529A (en) *	1995-09-29	1998-05-26	G.D. Searle & Co.	Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
US5840332A (en)	1996-01-18	1998-11-24	Perio Products Ltd.	Gastrointestinal drug delivery system
SK284330B6 (sk) *	1996-05-17	2005-01-03	Merck & Co., Inc.	Použitie 3-fenyl-4-(4-metylsulfonyl)fenyl)-2-(5H)-furanónu
US6586458B1 (en) *	1996-08-16	2003-07-01	Pozen Inc.	Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
KR100212449B1 (ko) *	1996-10-09	1999-08-02	이계철	무궁화 위성방송의 송/수신기 정합 방법
US6077539A (en) *	1996-11-12	2000-06-20	Pozen, Inc.	Treatment of migraine headache
EP0863134A1 (fr) *	1997-03-07	1998-09-09	Merck Frosst Canada Inc.	2-(3,5-difluorophényle)-3-(4-méthylesulphonylephényle)-2-cyclopentène-1-one comme inhibiteur de la cyclooxygénase-2
US20030225150A1 (en) *	1997-04-21	2003-12-04	Pharmacia Corporation	Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia
BR9809451A (pt) *	1997-05-22	2000-06-20	Searle & Co	Pirazóis substituìdos com 3(5)-heteroarila como inibidores de quinase p38.
NZ502990A (en) *	1997-08-27	2002-02-01	Hexal Ag	Pharmaceutical compositions of meloxicam with improved solubility and bioavailability
RS49982B (sr) *	1997-09-17	2008-09-29	Euro-Celtique S.A.,	Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
US6165506A (en) *	1998-09-04	2000-12-26	Elan Pharma International Ltd.	Solid dose form of nanoparticulate naproxen
TR200100708T2 (tr) *	1998-09-10	2001-07-23	Nycomed Danmark A/S	İlaç maddelerine mahsus çabuk salımlı farmasötik bileşimler.
US6440967B1 (en) *	1998-11-12	2002-08-27	Merck & Co., Inc.	Combination of a GABAA alpha 5 inverse agonist and COX-2 inhibitor, NSAID, estrogen or vitamin E
SA99191255B1 (ar)	1998-11-30	2006-11-25	جي دي سيرل اند كو	مركبات سيليكوكسيب celecoxib
AU3596500A (en)	1999-02-19	2000-09-04	Pozen, Inc.	Formulation of 5-ht agonists with cox-2 inhibitors

1999
- 1999-04-05 SA SA99191255A patent/SA99191255B1/ar unknown
- 1999-11-26 TN TNTNSN99223A patent/TNSN99223A1/fr unknown
- 1999-11-29 PE PE1999001189A patent/PE20001349A1/es active IP Right Grant
- 1999-11-29 AR ARP990106069A patent/AR020015A1/es not_active Application Discontinuation
- 1999-11-29 MA MA25858A patent/MA26709A1/fr unknown
- 1999-11-30 ES ES99961890T patent/ES2185412T3/es not_active Expired - Lifetime
- 1999-11-30 NZ NZ505762A patent/NZ505762A/en not_active IP Right Cessation
- 1999-11-30 PA PA19998486001A patent/PA8486001A1/es unknown
- 1999-11-30 IL IL13653299A patent/IL136532A/xx unknown
- 1999-11-30 EE EEP200000437A patent/EE04834B1/xx not_active IP Right Cessation
- 1999-11-30 DK DK99961890T patent/DK1049467T3/da active
- 1999-11-30 ME MEP-2008-544A patent/ME00416B/me unknown
- 1999-11-30 SK SK1106-2000A patent/SK283510B6/sk not_active IP Right Cessation
- 1999-11-30 GT GT199900203A patent/GT199900203A/es unknown
- 1999-11-30 JP JP2000584884A patent/JP3563036B2/ja not_active Expired - Lifetime
- 1999-11-30 CA CA002319201A patent/CA2319201C/fr not_active Expired - Lifetime
- 1999-11-30 WO PCT/US1999/028411 patent/WO2000032189A1/fr not_active Ceased
- 1999-11-30 HN HN1999000210A patent/HN1999000210A/es unknown
- 1999-11-30 AP APAP/P/2000/001874A patent/AP1637A/en active
- 1999-11-30 DE DE69903404T patent/DE69903404T2/de not_active Revoked
- 1999-11-30 PL PL341372A patent/PL200957B1/pl unknown
- 1999-11-30 TR TR2000/02207T patent/TR200002207T1/xx unknown
- 1999-11-30 AU AU18381/00A patent/AU748851B2/en not_active Expired
- 1999-11-30 UY UY25826A patent/UY25826A1/es not_active Application Discontinuation
- 1999-11-30 CN CNB998021857A patent/CN1154490C/zh not_active Ceased
- 1999-11-30 PT PT99961890T patent/PT1049467E/pt unknown
- 1999-11-30 KR KR10-2000-7008340A patent/KR100501034B1/ko not_active Ceased
- 1999-11-30 GE GEAP19995492A patent/GEP20022784B/en unknown
- 1999-11-30 SI SI9930144T patent/SI1049467T1/xx unknown
- 1999-11-30 UA UA2000074568A patent/UA58576C2/uk unknown
- 1999-11-30 EP EP99961890A patent/EP1049467B1/fr not_active Revoked
- 1999-11-30 OA OA1200000200A patent/OA11616A/en unknown
- 1999-11-30 HU HU0100867A patent/HUP0100867A3/hu not_active Application Discontinuation
- 1999-11-30 RS YUP-486/00A patent/RS50158B/sr unknown
- 1999-11-30 HR HR20000434A patent/HRP20000434B1/xx not_active IP Right Cessation
- 1999-11-30 AT AT99961890T patent/ATE225650T1/de not_active IP Right Cessation
- 1999-11-30 EA EA200000718A patent/EA003363B1/ru not_active IP Right Cessation
- 1999-11-30 CN CNB2004100375225A patent/CN1299683C/zh not_active Ceased
- 1999-11-30 KR KR10-2004-7009987A patent/KR20040065307A/ko not_active Ceased
- 1999-11-30 GC GCP1999388 patent/GC0000114A/xx active
- 1999-11-30 BR BR9908030-3A patent/BR9908030A/pt not_active Application Discontinuation
2000
- 2000-01-25 TW TW088120791A patent/TW579295B/zh not_active IP Right Cessation
- 2000-02-23 UY UY26025A patent/UY26025A1/es not_active Application Discontinuation
- 2000-05-31 ZA ZA200002722A patent/ZA200002722B/en unknown
- 2000-06-30 IS IS5555A patent/IS5555A/is unknown
- 2000-07-24 CU CU20000176A patent/CU20000176A7/es unknown
- 2000-07-25 NO NO20003815A patent/NO329912B1/no not_active IP Right Cessation
- 2000-07-27 CR CR6210A patent/CR6210A/es unknown
- 2000-08-09 BG BG104680A patent/BG64938B1/bg unknown
2004
- 2004-02-11 US US10/776,869 patent/US20050267189A1/en not_active Abandoned
2008
- 2008-01-14 US US12/013,873 patent/US20080167362A1/en not_active Abandoned
- 2008-03-28 CR CR9842A patent/CR9842A/es not_active Application Discontinuation
2012
- 2012-03-13 US US13/418,852 patent/US20120171284A1/en not_active Abandoned
2014
- 2014-09-23 US US14/493,921 patent/US9750756B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
KR100501034B1 (ko)	2005-07-18
BG104680A (en)	2001-02-28
CA2319201C (fr)	2006-07-11
PL341372A1 (en)	2001-04-09
RS50158B (sr)	2009-05-06
EA200000718A1 (ru)	2001-04-23
AU748851B2 (en)	2002-06-13
DK1049467T3 (da)	2003-02-10
ZA200002722B (en)	2000-11-29
HRP20000434A2 (en)	2000-08-31
IS5555A (is)	2000-06-30
EE04834B1 (et)	2007-06-15
YU48600A (sh)	2004-07-15
CA2319201A1 (fr)	2000-06-08
SA99191255B1 (ar)	2006-11-25
KR20010040484A (ko)	2001-05-15
AP1637A (en)	2006-07-17
CU20000176A7 (es)	2005-11-18
GT199900203A (es)	2001-11-15
CN1288378A (zh)	2001-03-21
BG64938B1 (bg)	2006-10-31
NO20003815D0 (no)	2000-07-25
IL136532A0 (en)	2001-06-14
TR200002207T1 (tr)	2000-12-21
PT1049467E (pt)	2003-02-28
KR20040065307A (ko)	2004-07-21
CN1154490C (zh)	2004-06-23
WO2000032189A1 (fr)	2000-06-08
PA8486001A1 (es)	2000-09-29
EP1049467A1 (fr)	2000-11-08
HK1069541A1 (en)	2005-05-27
DE69903404D1 (de)	2002-11-14
EA003363B1 (ru)	2003-04-24
OA11616A (en)	2004-09-10
IL136532A (en)	2003-01-12
ATE225650T1 (de)	2002-10-15
CR9842A (es)	2008-05-16
US20120171284A1 (en)	2012-07-05
PE20001349A1 (es)	2000-11-27
JP3563036B2 (ja)	2004-09-08
HUP0100867A2 (hu)	2002-03-28
HUP0100867A3 (en)	2002-05-28
TW579295B (en)	2004-03-11
US20050267189A1 (en)	2005-12-01
AU1838100A (en)	2000-06-19
HK1035144A1 (en)	2001-11-16
US20150011514A1 (en)	2015-01-08
US9750756B2 (en)	2017-09-05
AR020015A1 (es)	2002-03-27
NO20003815L (no)	2000-09-29
ME00416B (me)	2011-10-10
CR6210A (es)	2004-05-28
SK283510B6 (sk)	2003-08-05
EP1049467A4 (fr)	2001-08-08
GC0000114A (en)	2005-06-29
DE69903404T2 (de)	2003-08-14
PL200957B1 (pl)	2009-02-27
US20080167362A1 (en)	2008-07-10
EE200000437A (et)	2001-06-15
AP2000001874A0 (en)	2000-09-30
HRP20000434B1 (en)	2010-12-31
MA26709A1 (fr)	2004-12-20
NO329912B1 (no)	2011-01-24
NZ505762A (en)	2002-06-28
TNSN99223A1 (fr)	2005-11-10
UA58576C2 (uk)	2003-08-15
SK11062000A3 (sk)	2001-03-12
UY25826A1 (es)	2001-08-27
JP2002531403A (ja)	2002-09-24
CN1299683C (zh)	2007-02-14
GEP20022784B (en)	2002-09-25
SI1049467T1 (en)	2003-04-30
UY26025A1 (es)	2000-08-21
HN1999000210A (es)	2000-08-23
ES2185412T3 (es)	2003-04-16
EP1049467B1 (fr)	2002-10-09
CN1537531A (zh)	2004-10-20

Publication	Publication Date	Title
BR9908030A (pt)	2000-11-28	Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado
BR0012136A (pt)	2002-06-11	Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
BR0113447A (pt)	2003-07-08	Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica
BR0008060A (pt)	2002-02-05	Composições inibidoras de ciclooxigenase-2 tendo rápido inìcio de eficácia terapêutica
BR0314308A (pt)	2005-07-05	Composto, composição farmacêutica, métodos para bloquear uma combinação de mu, kappa, delta ou receptor (heterodìmero) dos mesmos em mamìferos, para tratar ou prevenir obesidade e doenças relacionadas, para suprimir o apetite em um paciente em necessidade deste, e para realizar a perda de peso em um paciente obeso, e, uso de um composto
BR9814389A (pt)	2000-10-10	Forma de dosagem farmacêutica revestida entérica, processo para a preparação da mesma, uso desta, pelota ou tablete encamado para a mesma, e, processos para melhorar a inibição da secreção de ácido gástrico, e para melhorar o efeito terapêutico no tratamento de distúrbios gastrointestinais associados com secreção de ácido em excesso
BR0008059A (pt)	2002-03-26	Composições de valdecoxib
BRPI0317463B8 (pt)	2021-05-25	composto, composição farmacêutica compreendendo o mesmo e uso do referido composto no preparo de um medicamento para tratar uma doença amilóide de transtiretina
BR9911073A (pt)	2001-02-20	Uso de uma composição compreendendo formoterol e budesonida para a prevenção ou tratamento de uma condição aguda de asma
BR122012014331A8 (pt)	2018-07-31	Formulações farmacêuticas
CA2442168A1 (fr)	2002-10-10	Composition de n-acetylcysteine et methodes de traitement et de prevention de la toxicite des medicaments
BR0015974A (pt)	2002-07-23	Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
BR0314943A (pt)	2005-08-02	Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes
BR0008058A (pt)	2002-03-26	Forma de estado sólido de celecoxib tendo biodisposnibilidade melhorada
MY117892A (en)	2004-08-30	Therapeutic compounds
BR0008847A (pt)	2001-12-26	Composições analgésicas que compreendemcompostos antiepilépticos, e métodos de uso dasmesmas
KR970061244A (ko)	1997-09-12	치매 치료용 약학 조성물
MY111260A (en)	1999-10-30	Pharmaceutical composition for the treatment of nicotine dependence
SE7612534L (sv)	1977-06-02	Forfarande for framstellning av farmaceutiska preparat for behandling av storningar i kalciumemnesomsettning
AR035946A1 (es)	2004-07-28	Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
MX9805441A (es)	1998-11-30	Compuestos terapeuticos.
BR112023000598A2 (pt)	2023-01-31	Composições de dose oral unitária composta de ibuprofeno e famotidina para o tratamento da dor aguda e redução da gravidade e/ou risco de azia
BR9908885A (pt)	2000-11-21	Medicamento para a profilaxia e/ou tratamento de mastocarcinoma, compreendendo um inibidor esteróide de aromatase
BR0212249A (pt)	2004-10-05	Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
MX2024008330A (es)	2025-01-09	Combinacion de obicetrapib e inhibidor de sglt2

Legal Events

Date	Code	Title	Description
2009-01-06	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2009-01-06	B15K	Others concerning applications: alteration of classification	Free format text: ALTERADA DA INT. CL.: A61K 9/14; A61K 9/20; A61K 31/415; A61K 31/18. Ipc: A61K 9/14 (2008.04), A61K 9/20 (2008.04), A61K 31/
2009-09-29	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE AS REIVINDICACOES 1 E SUAS DEPENDENTES ( 2 - 7 ) E INTERLIGADAS ( 8 E 9 ), NAO APRESENTAM O REQUISITO DE ATIVIDADE INVENTIVA, COMO DISPOSTO NOS ARTIGOS 8O E 13 DA LEI 9.279/96.
2010-07-13	B12B	Appeal against refusal [chapter 12.2 patent gazette]
2011-04-12	B15K	Others concerning applications: alteration of classification	Free format text: PARA INT.CL: A61K 9/14, A61K 9/20, A61K 31/415, A61K 31/18, A61P 29/00 Ipc: A61K 9/14 (2011.01), A61K 9/20 (2011.01), A61K 31/
2014-04-08	B15W	Others matters related to applications: legal action concerning application	Free format text: INPI-52400.104145/2014-83 ORIGEM: JUIZO DA 031A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0147752-50.2013.4.02.5101 ACAO ORDINARIA DE NULIDADE DA DECISAO ADMINISTRATIVA QUE MANTEVE O INDEFERIMENTO DO PEDIDO AUTOR: G.D. SEARLE LLC REU: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI E AGENCIA NACIONAL DE VIGILANCIA SANITARIA - ANVISA.
2019-07-09	B15N	Others concerning applications: notification of judicial decision	Free format text: INPI-52400.104145/2014-83 SECAO JUDICIARIA DO ESTADO DO RIO DE JANEIRO 31A VARA FEDERAL DO RIO DE JANEIRO PROCESSO: NO0147752-50.2013.4.02.5101AUTOR: G.D. SEARLE LLC REU: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI E AGENCIA NACIONAL DE VIGILANCIA SANITARIA - ANVISA DECISAO: DIANTE DO EXPOSTO, NOS TERMOS DA FUNDAMENTACAO, JULGO:I) EXTINTO O PROCESSO, SEM RESOLUCAO DO MERITO, NOS TERMOS DO ART.485, VI DO CPC, NO TOCANTE AO PEDIDO AUTORAL PARA DETERMINAR A ANVISA QUE ANUA O PEDIDO, FORMA DO DISPOSTO ART.229-C DA LPI.II) JULGO PARCIALMENTE PROCEDENTE O PEDIDO, PARA DECLARAR NULO O ATO ADMINISTRATIVO DE INDEFERIMENTO DA PATENTE PI 9908030-3, NOS TERMOS DO ART.487, I, DO CPC.
2019-07-30	B150	Others concerning applications: publication cancelled [chapter 15.30 patent gazette]	Free format text: ANULADA A PUBLICACAO CODIGO 15.14 NA RPI NO 2531 DE 09/07/2019 POR TER SIDO INDEVIDA, CONFORME O DISPOSTO A FOLHA 164 DO PROCESSO ADMINISTRATIVO INPI 52400.104145/2014-83, REFERENTE A ACAO JUDICIAL NO 0147752-50.2013.4.02.5101.